<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Clin Apher</span><span class="iso-abbrev" title="iso-abbrev">J Clin Apher</span><span class="doi" title="doi">10.1002/(ISSN)1098-1101</span><span class="publisher-id" title="publisher-id">JCA</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Clinical Apheresis</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">0733-2459</span><span class="issn-epub" tagx="issn" title="issn-epub">1098-1101</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley &amp;amp; Sons, LLC.</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Hoboken, USA</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7361338">7361338</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1002/jca.21806">10.1002/jca.21806</a></span><span class="publisher-id" title="publisher-id">JCA21806</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Concise Review</span>: <span class="subject" title="subject">Concise Review</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Convalescent plasma therapy in patients with <span class="styled-content" tagx="styled-content" title="styled-content">COVID</span>â€�19</div> <div class="alt-title" title="alt-title">
YiÄŸenoÄŸlu et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">YiÄŸenoÄŸlu</span><span class="given-names" tagx="given-names" title="given-names">TuÄŸÃ§e Nur</span></span><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0001-9962-8882</span><a href="#jca21806-aff-0001"><sup>1</sup></a><span class="address" title="address"><span class="email" tagx="email" title="email">dr.nuryigenoglu@gmail.com</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">HacÄ±bekiroÄŸlu</span><span class="given-names" tagx="given-names" title="given-names">Tuba</span></span><a href="#jca21806-aff-0002"><sup>2</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Berber</span><span class="given-names" tagx="given-names" title="given-names">Ä°lhami</span></span><a href="#jca21806-aff-0003"><sup>3</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dal</span><span class="given-names" tagx="given-names" title="given-names">Mehmet Sinan</span></span><a href="#jca21806-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BaÅŸtÃ¼rk</span><span class="given-names" tagx="given-names" title="given-names">AbdÃ¼lkadir</span></span><a href="#jca21806-aff-0004"><sup>4</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">NamdaroÄŸlu</span><span class="given-names" tagx="given-names" title="given-names">Sinem</span></span><a href="#jca21806-aff-0005"><sup>5</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Korkmaz</span><span class="given-names" tagx="given-names" title="given-names">Serdal</span></span><a href="#jca21806-aff-0006"><sup>6</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ulas</span><span class="given-names" tagx="given-names" title="given-names">Turgay</span></span><a href="#jca21806-aff-0007"><sup>7</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dal</span><span class="given-names" tagx="given-names" title="given-names">Tuba</span></span><a href="#jca21806-aff-0008"><sup>8</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Erkurt</span><span class="given-names" tagx="given-names" title="given-names">Mehmet Ali</span></span><a href="#jca21806-aff-0003"><sup>3</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turgut</span><span class="given-names" tagx="given-names" title="given-names">Burhan</span></span><a href="#jca21806-aff-0009"><sup>9</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">AltuntaÅŸ</span><span class="given-names" tagx="given-names" title="given-names">Fevzi</span></span><a href="#jca21806-aff-0001"><sup>1</sup></a><a href="#jca21806-aff-0010"><sup>10</sup></a></span></div><span class="citation_author_institution" id="jca21806-aff-0001">[1], <span class="named-content" title="named-content">Ankara Oncology Training and Research Hospital, Department of Hematology and Bone Marrow Transplantation Center</span><span class="institution" title="institution">University of Health Sciences</span><span class="city" tagx="city" title="city">Ankara</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0002">[2], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">Sakarya University</span><span class="named-content" title="named-content">Sakarya</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0003">[3], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">Inonu University</span><span class="city" tagx="city" title="city">Malatya</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0004">[4], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">Selcuk University</span><span class="city" tagx="city" title="city">Konya</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0005">[5], <span class="named-content" title="named-content">Bozyaka Training and Research Hospital, Department of Hematology</span><span class="institution" title="institution">University of Health Sciences</span><span class="city" tagx="city" title="city">Izmir</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0006">[6], <span class="named-content" title="named-content">Kayseri Training and Research Hospital, Department of Hematology</span><span class="institution" title="institution">University of Health Sciences</span><span class="city" tagx="city" title="city">Kayseri</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0007">[7], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">Near East University</span><span class="city" tagx="city" title="city">Nicosia</span><span class="country" tagx="country" title="country">Cyprus</span></span><span class="citation_author_institution" id="jca21806-aff-0008">[8], <span class="named-content" title="named-content">School of Medicine, Department of Clinical Microbiology</span><span class="institution" title="institution">Ankara YÄ±ldÄ±rÄ±m BeyazÄ±t University</span><span class="city" tagx="city" title="city">Ankara</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0009">[9], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">NamÄ±k Kemal University</span><span class="city" tagx="city" title="city">TekirdaÄŸ</span><span class="country" tagx="country" title="country">Turkey</span></span><span class="citation_author_institution" id="jca21806-aff-0010">[10], <span class="named-content" title="named-content">School of Medicine, Department of Internal Medicine, Division of Hematology</span><span class="institution" title="institution">Ankara YÄ±ldÄ±rÄ±m BeyazÄ±t University</span><span class="city" tagx="city" title="city">Ankara</span><span class="country" tagx="country" title="country">Turkey</span></span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span><b>Correspondence</b><br /><br /> TuÄŸÃ§e Nur YiÄŸenoÄŸlu, Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.<br /><br /> Email: <span class="email" tagx="email" title="email">dr.nuryigenoglu@gmail.com</span><br /><br /></div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-7-7</span></span><span class="elocation-id" tagx="elocation-id" title="elocation-id">10.1002/jca.21806</span><span class="history" title="history"><span class="received" title="received">received: 2020-4-23</span><span class="rev-recd" title="rev-recd">rev-recd: 2020-6-04</span><span class="accepted" title="accepted">accepted: 2020-6-10</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</span></span></div><a class="self-uri" href="file:JCA-9999-na.pdf" title="self-uri">file:JCA-9999-na.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>There are currently no licensed vaccines or therapeutics for COVIDâ€�19. Antiâ€�SARS CoVâ€�2 antibodyâ€�containing plasmas, obtained from the recovered individuals who had confirmed COVIDâ€�19, have been started to be collected using apheresis devices and stored in blood banks in some countries in order to administer to the patients with COVIDâ€�19 for reducing the need of intensive care and the mortality rates. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVIDâ€�19. CP may be an adjunctive treatment option to the antiâ€�viral therapy. The protective effect of CP may continue for weeks and months. After the assessment of the donor, 200â€�600â€‰mL plasma can be collected with apheresis devices. The donation interval may vary between countries. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVIDâ€�19. It could also be used for prophylactic purposes but the safety and effectiveness of this approach should be tested in randomized prospective clinical trials.</p> </div> <div class="kwd-group"> <div class="kwd" title="kwd">
convalescent plasma</div> <div class="kwd" title="kwd">
COVIDâ€�19</div> <div class="kwd" title="kwd">
SARS CoVâ€�2</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="source-schema-version-number" value="2.0" /> <meta name="edited-state" value="corrected-proof" /> <meta name="details-of-publishers-convertor" value="Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.5 mode:remove_FC converted:15.07.2020" /> </div> </div> <p content-type="self-citation"><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">YiÄŸenoÄŸlu</span><span class="given-names" tagx="given-names" title="given-names">TN</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">HacÄ±bekiroÄŸlu</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Berber</span><span class="given-names" tagx="given-names" title="given-names">Ä°</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Convalescent plasma therapy in patients with <span class="styled-content" tagx="styled-content" title="styled-content">COVID</span>â€�19</span>. <span class="source" tagx="source" title="source">J Clin Apher</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1002/jca.21806">10.1002/jca.21806</a></span></span></p> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1</span><div class="title" tagx="title" title="title">
INTRODUCTION</div> <p>At the end of 2019, pneumonia patients with an unidentified cause were started to be observed in Wuhan, Hubei Province, China.<a href="#jca21806-bib-0001"><sup>1</sup></a> After the genetic analysis of the virus, it was understood that these pneumonia cases were caused by the 2019 Novel Coronavirus (2019â€�nCoV).<a href="#jca21806-bib-0002"><sup>2</sup></a> On 11 February 2020; the disease was officially named as COVIDâ€�19, by the World Health Organization (WHO).<a href="#jca21806-bib-0003"><sup>3</sup></a> This novel coronavirus was named as SARSâ€�CoVâ€�2 by the International Committee on Taxonomy of Viruses.<a href="#jca21806-bib-0004"><sup>4</sup></a> It was declared a pandemic by the WHO on 11 March 2020. As of 17 April 2020, in the worldwide, there have been 2â€‰175â€‰130 confirmed cases of COVIDâ€�19, including 145â€‰184 deaths, as reported to WHO.<a href="#jca21806-bib-0003"><sup>3</sup></a> The mortality rate of COVIDâ€�19 is higher than the mortality rate of seasonal influenza in which the mortality rate is reported usually less than 0.1%.<a href="#jca21806-bib-0003"><sup>3</sup></a> Patients with any comorbidity and/or older age are associated with poorer clinical outcomes than younger patients or those without any comorbidity. As the number of comorbidities increases, the clinical outcome gets worse. Smoking, chronic obstructive pulmonary disease, diabetes, hypertension, cardiovascular diseases, and malignancy are reported to be the risk factors for severe COVIDâ€�19 and increased mortality.<a href="#jca21806-bib-0005"><sup>5</sup></a> Although there are clinical trials regarding the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVIDâ€�19. Because of the higher mortality rate and the high number of infected cases, it is important to find a treatment in a short time.</p> <p>Passive antibody therapy involves administering antibodies against a particular agent to a susceptible individual in order to protect or treat an infectious disease associated with this agent. On the contrary, active vaccination requires stimulation of an immune response that takes time to develop. Therefore, passive antibody administration is the only way to immunize susceptible people immediately. Passive antibody therapy has a history going back to the 1890s and was the only method of treating some infectious diseases before the development of antimicrobial therapy in the 1940s.<a href="#jca21806-bib-0006"><sup>6</sup></a> Currently, passive antibody therapy is mainly consisting of pooled immunoglobulin preparations that includes high concentrations of antibodies. On the other hand, CP has been used emergently in epidemics where there is insufficient time to produce immunoglobulin preparations.<a href="#jca21806-bib-0007"><sup>7</sup></a></p> <p>Antiâ€�SARS COVâ€�2 antibody containing plasma, obtained from the recovered individuals who had confirmed COVIDâ€�19, have been started to be collected by apheresis devices and stored in blood banks in some countries such as Turkey and the United States of America in hopes of reducing mortality rates and reduce the need of intensive care. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVIDâ€�19.</p> </div> <div class="treatmentofinfectiousdiseaseswithconvalescentplasma:historicalexamples" title="sec"><span class="label" tagx="label" title="label">2</span><div class="title" tagx="title" title="title">
TREATMENT OF INFECTIOUS DISEASES WITH CONVALESCENT PLASMA: HISTORICAL EXAMPLES</div> <p>In the past, plasmaâ€�mediated treatments have been used against many pathogens. Passive immunization obtained from sheep serum against diphtheria toxin was first given to a child with diphtheria in 1891 and saved his life. German scientist Emil Adolf von Behring received the 1901 Nobel Prize for his discovery of passive immunization against diphtheria toxin. CPs have been used in epidemics of viral infections like poliomyelitis, measles, mumps and flu.<a href="#jca21806-bib-0006"><sup>6</sup></a></p> <p>Experience in the use of CP against coronavirus was obtained from Severe Acute Respiratory Syndrome 1 (SARSâ€�COVâ€�1) outbreaks in 2003. In the retrospective nonâ€�randomized study conducted by Soo et al, 40 SARS patients refractory to ribavirin and 1.5 g of pulsed methylprednisolone received either 200â€�400â€‰mL CP (n = 19) or a further dose of pulsed methylprednisolone (n = 21). In patients who received CP, higher discharge rate up to 22â€‰days from the hospital (77.8% vs 23%; <i>P</i> = .004) and lower mortality rate (0% vs 23.8%; <i>P</i> = .049) was observed compared to the patients who received steroids. The authors also observed that patients receiving CP after day 16 had a poor clinical response and concluded that CP administration was more effective when given early in the course of the disease.<a href="#jca21806-bib-0008"><sup>8</sup></a> In Taiwan, Yeh et al reported three healthcare workers with SARSâ€�COVâ€�1, who had failed to respond to steroids, ribavirin, intravenous immunoglobulin and protease inhibitors, were treated with 500â€‰mL CP. All of the patients survived after CP transfusion.<a href="#jca21806-bib-0009"><sup>9</sup></a> Besides, Cheng et al evaluated the efficacy of CP in the treatment of patients with SARS in 2003 and found a higher dayâ€�22 discharge rate among patients who received CP before day 14 of illness.<a href="#jca21806-bib-0010"><sup>10</sup></a></p> <p>CP was also used in the West African Ebola epidemic in 2013. Eightyâ€�four patients received 500â€‰mL of CP. When compared to the historical control group, the CP group had a shorter duration of symptoms than did the control group. From day 3 to day 16 after diagnosis, the risk of death was 31% in the CP group and 38% in the control group. Even though the transfusion of up to 500â€‰mL CP improved the symptoms, no significant survival benefit was observed.<a href="#jca21806-bib-0011"><sup>11</sup></a> Treatment with CP was also reported in three patients with Middle East Respiratory Syndrome (MERS) in South Korea. In this study, 3 of 13 MERS patients with respiratory failure received 4 CP infusions from recovered MERSâ€�CoVâ€�infected patients, and only two of them showed neutralizing activity. After the infusion of CP with a neutralizing activity titer of 1:80, serological response was achieved but no response was achieved after the infusions of CP with a neutralizing activity titer of 1:40.<a href="#jca21806-bib-0012"><sup>12</sup></a>, <a href="#jca21806-bib-0013"><sup>13</sup></a></p> </div> <div class="treatmentofcovidâ€�19withconvalescentplasma" title="sec"><span class="label" tagx="label" title="label">3</span><div class="title" tagx="title" title="title">
TREATMENT OF <span class="styled-content" tagx="styled-content" title="styled-content">COVID</span>â€�19 WITH CONVALESCENT PLASMA</div> <p>CP has been used in the recent global outbreak for the treatment of patients with COVIDâ€�19 in China. In the study conducted by Shen et al, 5 critically ill COVIDâ€�19 patients refractory to steroid and antiviral treatment, received 400â€‰mL CP from 5 different donors. All the donors had SARSâ€�CoVâ€�2â€�specific ELISA antibody titer higher than 1:1000; and neutralizing antibody titer greater than 40. After CP transfusion; in 4 (80%) of 5 patients, the body temperature normalized within 3â€‰days; the Sequential Organ Failure Assessment Score decreased, and PaO<sub>2</sub>/FiO<sub>2</sub> increased within 12â€‰days (range, first 172â€�276 and then 284â€�366); viral loads decreased and became negative within 12â€‰days; ELISA and neutralizing antibody titers increased. After 12â€‰days, acute respiratory distress syndrome (ARDS) improved in 4 patients (80%); after 2â€‰weeks, 3 patients extubated; 3 of the 5 patients (60%) were discharged from the hospital and the other two patients were stable after 37â€‰days.<a href="#jca21806-bib-0014"><sup>14</sup></a> In a recent study, researchers treated 10 critically ill COVIDâ€�19 patients with antiviral therapy and steroid, plus a dose of 200â€‰mL CP that had a neutralized antibody titer of at least 1:640. Researchers prospectively compared symptoms and laboratory findings 3â€‰days after CP infusion. Among all patients, CP was well tolerated. It significantly increased neutralizing antibodies at a high level; within 7â€‰days, viremia disappeared; clinical symptoms resolved rapidly in 3â€‰days. There was an improvement in lymphocyte count and in SaO<sub>2</sub>; on radiological examination, they reported that lung lesions changed significantly within 7â€‰days.<a href="#jca21806-bib-0015"><sup>15</sup></a> Although these studies involve a small number of patients, available information suggests that CP administration is safe and reduces the viral load.</p> <p>On March 24, the American Food and Drug Administration (FDA) published a recommendation with the â€œCOVIDâ€�19 Convalescent Plasma Research â€� Emergencyâ€� declaration. FDA stated that certain standards have been established for donation and that CP use is allowed for patients under certain conditions. Of note, FDA does not allow the use of CP for prophylaxis. With the â€œBlood Regulatory Networkâ€�, WHO suggested using CP when vaccines and antiâ€�viral drugs are not available in the treatment of critically ill patients with COVIDâ€�19.<a href="#jca21806-bib-0016"><sup>16</sup></a></p> <p>Turkish Ministry of Health allowed the use of CP in severe COVIDâ€�19.<a href="#jca21806-bib-0017"><sup>17</sup></a> Therapeutic apheresis centers licensed by the Ministry of Health and Turkish Red Crescent carry out activities for obtaining CP from donors. In Turkey, multidisciplinary working groups which have been attended by a large number of scientists were formed. These groups provide information and experience sharing among themselves by following donor selection, product standard, treatment management, patientâ€�donor followâ€�up, and scientific developments in the world. CP administrations are carried out under the control of intensive care, infectious disease specialists and pulmonologists.</p> </div> <div class="convalescentplasma:themechanismofaction" title="sec"><span class="label" tagx="label" title="label">4</span><div class="title" tagx="title" title="title">
CONVALESCENT PLASMA: THE MECHANISM OF ACTION</div> <p>The exact mechanism of CP in COVIDâ€�19 has not been clearly identified yet. However, previous studies revealed that the mechanism of action of CP in other viral infections such as Ebola virus and Respiratory Syncytial Virus is mainly viral neutralization. The other mechanisms are antibodyâ€�induced cellular cytotoxicity, complement activation and phagocytosis. Neutralizing antibodies delivered with CP can provide control of the viral load. Nonâ€�neutralizing antibodies may also contribute to prophylaxis and/or enhance recovery.<a href="#jca21806-bib-0018"><sup>18</sup></a>, <a href="#jca21806-bib-0019"><sup>19</sup></a></p> </div> <div class="stepsoftheconvalescentplasmacollections" title="sec"><span class="label" tagx="label" title="label">5</span><div class="title" tagx="title" title="title">
STEPS OF THE CONVALESCENT PLASMA COLLECTIONS</div> <p>The regulations of every single step of CP collections is very important. Starting from assessment of donor to the administration of CP to the patients, all of the steps should be organized carefully and should be performed by experienced health workers.</p> <div class="donoreligibility" title="sec"><span class="label" tagx="label" title="label">5.1</span><div class="title" tagx="title" title="title">
Donor eligibility</div> <p>The criteria for eligibility of CP donors may vary between countries. According to the FDA, individuals who meet the following criteria can be a CP donor<a href="#jca21806-bib-0016"><sup>16</sup></a>: </p><ol> <li> <p>Recovered from COVIDâ€�19, blood donor tests were done and suitable for donation;</p> </li> <li> <p>Evidence of COVIDâ€�19 documented by a laboratory test either by a diagnostic test (eg, nasopharyngeal swab) at the time of illness, or a positive serological test for SARSâ€�CoVâ€�2 antibodies after recovery, if prior diagnostic testing was not performed at the time COVIDâ€�19 was suspected.</p> </li> <li> <p>Complete resolution of symptoms at least 14â€‰days prior to donation.</p> </li> <li> <p>Male donors, or female donors who have not been pregnant, or female donors who have been tested since their most recent pregnancy and results interpreted as negative for HLA antibodies.</p> </li> <li> <p>When measurement of neutralizing antibody titers is available, neutralizing antibody titers of at least 1:160 is recommended. A titer of 1:80 may be considered acceptable if an alternative matched unit is not available.</p> </li> </ol> <p /> </div> <div class="preâ€�donationevaluationofdonors" title="sec"><span class="label" tagx="label" title="label">5.2</span><div class="title" tagx="title" title="title">
Preâ€�donation evaluation of donors</div> <p>Realâ€�time reverse transcriptaseâ€�PCR (RTâ€�PCR) is currently a favored assay for the detection of coronavirus. However, RNA detectability was low in samples collected before dayâ€�7 and during days 15â€�39. For this reason, coronavirus preâ€�donation screening tests should be supported by antibody detecting tests.<a href="#jca21806-bib-0020"><sup>20</sup></a> Each donor must meet all eligibility criteria and be evaluated by all test required for normal blood donation. Female donors with a history of pregnancy should be screened for HLA antibodies to minimize the risk of transfusionâ€�related acute lung injury (TRALI). In addition, a blood sample should be obtained for antibody testing before referring the donor to an apheresis procedure. Unfortunately, neutralizing antibody assays are not available in most centers. Quantitative assays (eg, ELISA) are available but commercially available assays have not been optimally validated. In addition, the relationship between total antiâ€�SARSâ€�CoVâ€�2 antibodies and neutralizing antiâ€�SARSâ€�CoVâ€�2 antibodies is not clear. There is also uncertainty as to whether total antibodies or subclasses (eg, IgM, IgG, or IgA) are the optimal measures, and which antigen is most informative.<a href="#jca21806-bib-0021"><sup>21</sup></a>, <a href="#jca21806-bib-0022"><sup>22</sup></a> Limited data are currently available on the ELISAs. In a previous study, the efficacy of the antibody test for the detection of IgM and IgG, has shown a sensitivity and specificity of 88.7% and 90.6%, respectively. The antibody titer will differ according to the duration between the collection time and onset of infection. In previous studies, seroconversion has been observed to occur between 8 and 21â€‰days after the onset of symptoms.<a href="#jca21806-bib-0022"><sup>22</sup></a>, <a href="#jca21806-bib-0023"><sup>23</sup></a>, <a href="#jca21806-bib-0024"><sup>24</sup></a>, <a href="#jca21806-bib-0025"><sup>25</sup></a> In a study conducted in 173 patients with COVIDâ€�19, the seroconversion rate for total antibodies (Ab), IgM and IgG was 93.1%, 82.7%, and 64.7%, respectively. The median seroconversion time for total Ab, IgM and then IgG were dayâ€�11, dayâ€�12 and dayâ€�14, separately. The presence of antibodies was &amp;lt;40% within 1â€�week since onset but rapidly increased to 100.0% (total Ab), 94.3% (IgM), and 79.8% (IgG) since dayâ€�15 after onset. RNA detectability decreased from 66.7% in samples collected before dayâ€�7 to 45.5% during days 15â€�39. The authors suggested that combining RNA and antibody detections significantly improved the sensitivity of diagnosis for COVIDâ€�19 in the first 1â€�week since onset.<a href="#jca21806-bib-0026"><sup>26</sup></a> Currently, the findings that have been reported suggest that CPs that are collected â‰¥14â€‰days after resolution of symptoms contain high titers of antibodies.<a href="#jca21806-bib-0022"><sup>22</sup></a>, <a href="#jca21806-bib-0023"><sup>23</sup></a>, <a href="#jca21806-bib-0024"><sup>24</sup></a>, <a href="#jca21806-bib-0025"><sup>25</sup></a> According to FDA if testing can be conducted, neutralizing antibody titers should be at least 1:160 but a titer of 1:80 may be considered acceptable if an alternative matched unit is not available.<a href="#jca21806-bib-0016"><sup>16</sup></a></p> </div> <div class="donorrecruitment" title="sec"><span class="label" tagx="label" title="label">5.3</span><div class="title" tagx="title" title="title">
Donor recruitment</div> <p>Blood centers may play a role in recruitment of donors in collaboration with partner hospitals. In Turkey, therapeutic apheresis centers licensed by the Ministry of Health and Turkish Red Crescent carry out activities for obtaining CP from donors.</p> </div> <div class="collectionofconvalescentplasmaatapheresiscenters" title="sec"><span class="label" tagx="label" title="label">5.4</span><div class="title" tagx="title" title="title">
Collection of convalescent plasma at apheresis centers</div> <p>Donors who have successfully completed preâ€�donation evaluation are directed to the apheresis centers. CP should be collected by apheresis to take larger volumes in short intervals. Approximately 200â€�600â€‰mL plasma can be collected with apheresis devices depending on the total blood volume of the donor. The collected plasma volume (excluding the anticoagulant solution) should not exceed 750â€‰mL for each procedure. With the consent of the donor, an appointment can be arranged for plasma donation again. The donation interval may vary between countries. CP is stored by freezing or applied within 6 hours without freezing. Freezing should be started within the first 6 hours after the apheresis process is completed. Plasma components should be labeled using the ISBT128 coding system for traceability. The collected products can be individually labeled as 200â€‰mL of divided ingredients and defined as 1 unit. Barcoded products should be stored at or below minus 18/25Â° in a separate storage cabinet. Appropriate patients can be given 200â€�400â€‰mL of CP in accordance with the clinical research protocol. ABO blood group should preferably be compatible. For pathogen inactivation process; amotosalenâ€‰+â€‰UV light, riboflavinâ€‰+â€‰UV light, methylene blue or a solvent/detergent may be used. But we would like to highlight that there has been no study that compared Antiâ€�SARSâ€�CoVâ€�2 CP that had undergone pathogen inactivation process to those of not. In order to maximize transfusion safety, it is recommended that the CP should undergone pathogen inactivation process. It should be irradiated if it will be given to the patient without being frozen within 6 hours after the plasma collection. Otherwise, the frozen plasma does not need to be irradiated.</p> </div> </div> <div class="thedoseofconvalescentplasma" title="sec"><span class="label" tagx="label" title="label">6</span><div class="title" tagx="title" title="title">
THE DOSE OF CONVALESCENT PLASMA</div> <p>In the previous studies, the dosing of CP is highly variable. In clinical trials, one unit of plasma (200â€‰mL) has been planned for use for prophylaxis and one to two units have been planned for treatment. The antibodies' duration of efficacy is unknown but is estimated to last in weeks to a few months.<a href="#jca21806-bib-0025"><sup>25</sup></a>, <a href="#jca21806-bib-0027"><sup>27</sup></a>, <a href="#jca21806-bib-0028"><sup>28</sup></a> In previous use of CP therapy in SARS, 5 mL/kg of plasma at a titer of 1:160 was used.<a href="#jca21806-bib-0010"><sup>10</sup></a> A quarter or half of the treatment dose was used for prophylactic purposes in earlier studies. According to linear proportionality, 3.125â€‰mL/kg of plasma with a titer of &amp;gt;1:64 would provide an equivalent immunoglobulin level to oneâ€�quarter of 5 mL/kg plasma with a titer of 1:160.<a href="#jca21806-bib-0007"><sup>7</sup></a></p> <p>In pediatric transfusions, dose by body weight should be used. COVIDâ€�19 is rarely symptomatic in the pediatric age group. Therefore, every procedure in this age group should be performed within the scope of clinical research in cooperation with national and international health authorities.</p> </div> <div class="patientselection" title="sec"><span class="label" tagx="label" title="label">7</span><div class="title" tagx="title" title="title">
PATIENT SELECTION</div> <p>There are several clinical trials that are ongoing that have very different eligibility criteria from the severely affected to post exposure individuals.<a href="#jca21806-bib-0029"><sup>29</sup></a> The patient selection may vary between countries. The FDA allowed the use of CP to patients who met the following criteria<a href="#jca21806-bib-0016"><sup>16</sup></a>: </p><ul> <li> <p>Laboratory confirmed COVIDâ€�19</p> </li> <li> <p>Severe or immediately lifeâ€�threatening COVIDâ€�19.</p> <ul> <li> <p>Severe disease is defined as one or more of the following:</p> <ul> <li> <p>Dyspnea,</p> </li> <li> <p>Tachypneaâ€‰â‰¥â€‰30/min,</p> </li> <li> <p>blood oxygen saturationâ€‰â‰¤â€‰93%,</p> </li> <li> <p>PaO<sub>2</sub>/FiO<sub>2</sub>â€‰<div class="â€‰300,_UNKNOWN" /></p> </li> <li> <p>lung infiltrates &amp;gt;50% within 24â€�48â€‰hours</p> </li> </ul> </li> <li> <p>The lifeâ€�threatening disease is defined as one or more of the following:</p> <ul> <li> <p>respiratory failure,</p> </li> <li> <p>septic shock,</p> </li> <li> <p>multiple organ dysfunction</p> </li> </ul> </li> </ul> </li> </ul> <p /> </div> <div class="prophylaxis" title="sec"><span class="label" tagx="label" title="label">8</span><div class="title" tagx="title" title="title">
PROPHYLAXIS</div> <p>There is no clear indication and evidence of benefit by using CP for prophylaxis for those who have been exposed to SARSâ€�CoVâ€�2, this issue is still controversial and FDA does not allow the use of CP for prophylaxis outside of approved clinical trials.<a href="#jca21806-bib-0007"><sup>7</sup></a>, <a href="#jca21806-bib-0016"><sup>16</sup></a> However, historically, it has been stated that passive antibody therapy is most effective when administered prophylactically or used early after the onset of symptoms.<a href="#jca21806-bib-0030"><sup>30</sup></a>, <a href="#jca21806-bib-0031"><sup>31</sup></a> The new, phase 2â€�3 trial is recruiting patients and still evaluating the use of postâ€�exposure prophylactic plasma in COVIDâ€�19 patients who have had close contact exposure, but have not yet presented symptoms.<a href="#jca21806-bib-0032"><sup>32</sup></a></p> </div> <div class="risksofconvalescentplasma" title="sec"><span class="label" tagx="label" title="label">9</span><div class="title" tagx="title" title="title">
RISKS OF CONVALESCENT PLASMA</div> <p>The risks of CP administration are similar to those of standard plasma. Infection with another infectious disease agent (viral transmission or bacterial contamination), immunological reactions such as serum disease, nonâ€�hemolytic transfusion reactions (tremors, fever, urticaria), transfusionâ€�associated circulatory overload and TRALI can be observed.<a href="#jca21806-bib-0033"><sup>33</sup></a> No serious adverse events have been reported in any study of CP. Two observational studies during the SARSâ€�CoVâ€�1 outbreak did not report any complications related to CP.<a href="#jca21806-bib-0008"><sup>8</sup></a> In developed countries, for HIV, hepatitis B and hepatitis C viruses, the risk of transfusionâ€�transmissible infection is less than one infection per two million donations.<a href="#jca21806-bib-0034"><sup>34</sup></a> The risk of TRALI is generally less than one for every 5000 transfused units, but in COVIDâ€�19, the risk of TRALI is one of the major concerns about CP because most of the critically ill patients have ARDS and disseminated intravascular coagulation. Both of these situations are risk factors for the development of TRALI.<a href="#jca21806-bib-0035"><sup>35</sup></a> Specific risk about Antiâ€�SARSâ€�CoVâ€�2 CP is transfusionâ€�transmitted SARSâ€�CoVâ€�2. This remains theoretical because there has been no report of SARSâ€�CoVâ€�2 transmission by blood transfusion. This risk is particularly important in prophylactic use since critically ill patients are already infected. In addition, only 1% of symptomatic patients have been reported to have detectable SARSâ€�CoVâ€�2 RNA in their blood.<a href="#jca21806-bib-0036"><sup>36</sup></a>, <a href="#jca21806-bib-0037"><sup>37</sup></a> Between January 25 to March 4, 2020; 2430 blood donations were screened in Wuhan and only one (0.04%) donor was found to be positive for SARSâ€�CoVâ€�2 RNA. Between December 21 to January 22, 2020; 4995 blood donations were screened and a second (0.02%) donor was found to be positive for SARSâ€�CoVâ€�2 RNA.<a href="#jca21806-bib-0038"><sup>38</sup></a> The other theoretical risk of CP is an antibodyâ€�dependent enhancement (ADE). Antibodies that developed during a previous infectious disease caused by a different viral serotype may exacerbate clinical severity.<a href="#jca21806-bib-0039"><sup>39</sup></a> Previous infection with other types of coronavirus may arise the concern about the risk of ADE in COVIDâ€�19 and the geographic variation in disease severity may be attributed to this mechanism.<a href="#jca21806-bib-0040"><sup>40</sup></a> In the current pandemic, there has been no report about the worsening of the clinical situation that has been attributed to ADE after CP infusion. Similarly, there has been no report about ADE after the use of CP for SARS and MERS. The other theoretical risk of CP is the attenuation of the development of a natural immune response, especially when administered for prophylaxis. CP treatment is recommended only in academic or comprehensive centers that can manage potential treatmentâ€�related complications, such as TRALI.</p> <p>In conclusion, SARSâ€�CoVâ€�2 continues to spread worldwide. The exact treatment of COVIDâ€�19 disease is currently unknown. Even though limited published studies are not prospective or randomized, until the development of vaccines or therapeutics, CP seems to be a safe and probably effective treatment for critically ill patients with COVIDâ€�19. At least preliminary results of multicentre randomized controlled clinical trials should be waited. Meanwhile, in this pandemic, scientists should be encouraged to collaborate on common research protocols, rather than conducting independent researches. International multicenter randomized controlled trials are needed. CP use should be encouraged to be made within the scope of clinical trials in cooperation with national and international health authorities.</p> </div> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
CONFLICT OF INTEREST</div> <p>The authors have no conflicts of interest to disclose.</p> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
ACKNOWLEDGEMENTS</div> <p>There is no acknowledgement.</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
REFERENCES</div> <li tag="ref"><a name="jca21806-bib-0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wu</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Early transmission dynamics in Wuhan, China, ofNovel coronavirusâ€�infected pneumonia</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">382</span>:<span class="fpage" tagx="fpage" title="fpage">1199</span>â€�<span class="lpage" tagx="lpage" title="lpage">1207</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31995857">31995857</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">A novel coronavirus from patients with pneumoniain China, 2019</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">382</span>:<span class="fpage" tagx="fpage" title="fpage">727</span>â€�<span class="lpage" tagx="lpage" title="lpage">733</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31978945">31978945</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: World Health Organization Press Conference</span> . The World Health Organization (WHO) has officially named the disease caused by the novel coronavirus as COVIDâ€�19. <a href="https://www.who.int/emergencies/diseases/novel%2010coronavirus%20102019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</a>. Accessed on April 17, <span class="year" tagx="year" title="year">2020</span>.</span></li> <li tag="ref"><a name="jca21806-bib-0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gorbalenya</span><span class="given-names" tagx="given-names" title="given-names">AE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Baker</span><span class="given-names" tagx="given-names" title="given-names">SC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Baric</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Severe acute respiratory syndromeâ€�related coronavirus: the species and its viruses â€� a statement of the Coronavirus Study Group</span>. <span class="source" tagx="source" title="source">bioRxiv</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.02.07.937862">10.1101/2020.02.07.937862</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">WJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liang</span><span class="given-names" tagx="given-names" title="given-names">WH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Comorbidity and its impact on 1590 patients with Covidâ€�19 in China: a nationwide analysis</span>. <span class="source" tagx="source" title="source">Eur Respir J</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">55</span>:<span class="fpage" tagx="fpage" title="fpage">2000547</span><span class="pub-id"><a href="https://dx.doi.org/10.1183/13993003.00547-2020">10.1183/13993003.00547-2020</a></span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32217650">32217650</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Graham</span><span class="given-names" tagx="given-names" title="given-names">BS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ambrosino</span><span class="given-names" tagx="given-names" title="given-names">DM</span></span>. <span class="mixed-article-title" title="mixed-article-title">History of passive antibody administration forprevention and treatment of infectious diseases</span>. <span class="source" tagx="source" title="source">Curr Opin HIV AIDS</span>. <span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">129</span>â€�<span class="lpage" tagx="lpage" title="lpage">134</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25760933">25760933</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bloch</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shoham</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Deployment ofconvalescent plasma for the prevention and treatment of COVIDâ€�19</span>. <span class="source" tagx="source" title="source">J Clin Invest</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">130</span>:<span class="fpage" tagx="fpage" title="fpage">2757</span>â€�<span class="lpage" tagx="lpage" title="lpage">2765</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1172/JCI138745">10.1172/JCI138745</a></span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32254064">32254064</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soo</span><span class="given-names" tagx="given-names" title="given-names">YO</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wong</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Retrospective comparison of convalescent plasma with continuinghighâ€�dose methylprednisolone treatment in SARS patients</span>. <span class="source" tagx="source" title="source">Clin Microbiol Infect</span>. <span class="year" tagx="year" title="year">2004</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">676</span>â€�<span class="lpage" tagx="lpage" title="lpage">678</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15214887">15214887</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yeh</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chiueh</span><span class="given-names" tagx="given-names" title="given-names">TS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Siu</span><span class="given-names" tagx="given-names" title="given-names">LK</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Experience of using convalescent plasma for severeacute respiratory syndrome among healthcare workers in a Taiwan hospital</span>. <span class="source" tagx="source" title="source">J Antimicrob Chemother</span>. <span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">56</span>:<span class="fpage" tagx="fpage" title="fpage">919</span>â€�<span class="lpage" tagx="lpage" title="lpage">922</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/16183666">16183666</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wong</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Soo</span><span class="given-names" tagx="given-names" title="given-names">YO</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Use of convalescent plasma therapy in SARS patients in Hong Kong</span>. <span class="source" tagx="source" title="source">Eur J Clin Microbiol Infect Dis</span>. <span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">44</span>â€�<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/15616839">15616839</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">van Griensven</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Edwards</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">de Lamballerie</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Evaluation of convalescent plasma for Ebola virus disease in Guinea</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">374</span>:<span class="fpage" tagx="fpage" title="fpage">33</span>â€�<span class="lpage" tagx="lpage" title="lpage">42</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26735992">26735992</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ko</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Seok</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cho</span><span class="given-names" tagx="given-names" title="given-names">SY</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirusinfection: a single centre experience</span>. <span class="source" tagx="source" title="source">Antivir Ther</span>. <span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">23</span>:<span class="fpage" tagx="fpage" title="fpage">617</span>â€�<span class="lpage" tagx="lpage" title="lpage">622</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29923831">29923831</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Arabi</span><span class="given-names" tagx="given-names" title="given-names">YM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hajeer</span><span class="given-names" tagx="given-names" title="given-names">AH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Luke</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Feasibility of using convalescent plasma immunotherapy for MERSâ€�CoV infection, Saudi Arabia</span>. <span class="source" tagx="source" title="source">Emerg Infect Dis</span>. <span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">1554</span>â€�<span class="lpage" tagx="lpage" title="lpage">1561</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27532807">27532807</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shen</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Treatment of 5 critically ill patients with COVIDâ€�19 with convalescent plasma</span>. <span class="source" tagx="source" title="source">Jama</span>. <span class="year" tagx="year" title="year">2020</span> Mar 27;<span class="volume" tagx="volume" title="volume">323</span>:<span class="fpage" tagx="fpage" title="fpage">1582</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2020.4783">10.1001/jama.2020.4783</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Duan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Effectiveness of convalescent plasmatherapy in severe COVIDâ€�19 patients</span>. <span class="source" tagx="source" title="source">Proc Natl Acad Sci U S A</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">117</span>(<span class="issue" tagx="issue" title="issue">17</span>):<span class="fpage" tagx="fpage" title="fpage">9490</span>â€"<span class="lpage" tagx="lpage" title="lpage">9496</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1073/pnas.2004168117">10.1073/pnas.2004168117</a></span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32253318">32253318</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: FDA</span> . Investigational covidâ€�19 convalescent plasmaâ€"emergency INDs. <a href="https://www.fda.gov/vaccines%2010blood%2010biologics/investigational%2010new%2010drug%2010ind%2010or%2010device%2010exemption%2010ideprocess%2010cber/investigational%2010covid%201019%2010convalescent%2010plasma%2010emergency%2010inds">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ideprocess-cber/investigational-covid-19-convalescent-plasma-emergency-inds</a>. Accessed May 11, <span class="year" tagx="year" title="year">2020</span>.</span></li> <li tag="ref"><a name="jca21806-bib-0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: Turkish Ministry of Health</span> . <a href="https://dosyamerkez.saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0">https://dosyamerkez.saglik.gov.tr/Eklenti/37163,covid-19-immun-plazma-rehberi-12-nisan-2020-sonv1-ti-neopdfpdf.pdf?0</a>. Accessed April 17, <span class="year" tagx="year" title="year">2020</span>.</span></li> <li tag="ref"><a name="jca21806-bib-0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">van Erp</span><span class="given-names" tagx="given-names" title="given-names">EA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Luytjes</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ferwerda</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">van Kasteren</span><span class="given-names" tagx="given-names" title="given-names">PB</span></span>. <span class="mixed-article-title" title="mixed-article-title">Fcâ€�mediated antibody effector functions during respiratory syncytial virus infection and disease</span>. <span class="source" tagx="source" title="source">Front Immunol</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">548</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30967872">30967872</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gunn</span><span class="given-names" tagx="given-names" title="given-names">BM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yu</span><span class="given-names" tagx="given-names" title="given-names">WH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Karim</span><span class="given-names" tagx="given-names" title="given-names">MM</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">A role for fc function in therapeutic monoclonal antibodyâ€�mediated protection against Ebola virus</span>. <span class="source" tagx="source" title="source">Cell Host Microbe</span>. <span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">221</span>â€�<span class="lpage" tagx="lpage" title="lpage">233</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30092199">30092199</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ozma</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Maroufi</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khodadadi</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Clinical manifestation, diagnosis, prevention and control of SARSâ€�CoVâ€�2 (COVIDâ€�19) during the outbreak period</span>. <span class="source" tagx="source" title="source">Infez Med</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">28</span>:<span class="fpage" tagx="fpage" title="fpage">153</span>â€�<span class="lpage" tagx="lpage" title="lpage">165</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32275257">32275257</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Amanat</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Nguyen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chromikova</span><span class="given-names" tagx="given-names" title="given-names">V</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">A serological assay to detect SARSâ€�CoVâ€�2 seroconversion in humans</span>. <span class="source" tagx="source" title="source">medRxiv</span>. <span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.03.17.20037713">10.1101/2020.03.17.20037713</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Okba</span><span class="given-names" tagx="given-names" title="given-names">NMA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Muller</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">SARSâ€�CoVâ€�2 specific antibody responses in COVIDâ€�19 patients</span>. <span class="source" tagx="source" title="source">medRxiv</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.03.18.20038059">10.1101/2020.03.18.20038059</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yi</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Luo</span><span class="given-names" tagx="given-names" title="given-names">X</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Development and clinical application of a rapid IgMâ€�IgG combined antibody test for SARSâ€�CoVâ€�2 infection diagnosis</span>. <span class="source" tagx="source" title="source">J Med Virol</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1002/jmv.25727">10.1002/jmv.25727</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Guo</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ren</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Profiling early humoral response to diagnose novel coronavirus disease (COVIDâ€�19)</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span>. <span class="year" tagx="year" title="year">2020</span> pii: ciaa310. <span class="pub-id"><a href="https://dx.doi.org/10.1093/cid/ciaa310">10.1093/cid/ciaa310</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Duan</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">The Feasibility of Convalescent Plasma Therapy in Severe COVIDâ€�19 Patientss:a Pilot Study</span>. <span class="source" tagx="source" title="source">medRxiv</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1101/2020.03.16.20036145">10.1101/2020.03.16.20036145</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yuan</span><span class="given-names" tagx="given-names" title="given-names">Q</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Antibody responses to SARSâ€�CoVâ€�2 in patients of novel coronavirus disease 2019</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span>. <span class="year" tagx="year" title="year">2020</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/cid/ciaa344">10.1093/cid/ciaa344</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Scharff</span><span class="given-names" tagx="given-names" title="given-names">MD</span></span>. <span class="mixed-article-title" title="mixed-article-title">Return to the past: the case for antibodyâ€�basedtherapies in infectious diseases</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span>. <span class="year" tagx="year" title="year">1995</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">150</span>â€�<span class="lpage" tagx="lpage" title="lpage">161</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7578724">7578724</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>. <span class="mixed-article-title" title="mixed-article-title">Passive antibody administration (immediate immunity) as aspecific defense against biological weapons</span>. <span class="source" tagx="source" title="source">Emerg Infect Dis</span>. <span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">8</span>:<span class="fpage" tagx="fpage" title="fpage">833</span>â€�<span class="lpage" tagx="lpage" title="lpage">841</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12141970">12141970</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><a href="https://clinicaltrials.gov/ct2/results?cond=convalescent%2Bplasma">https://clinicaltrials.gov/ct2/results?cond=convalescent+plasma</a>. Accessed May 11, 2020.</span></li> <li tag="ref"><a name="jca21806-bib-0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pirofski</span><span class="given-names" tagx="given-names" title="given-names">LA</span></span>. <span class="mixed-article-title" title="mixed-article-title">Antibodyâ€�mediated regulation of cellular immunityand the inflammatory response</span>. <span class="source" tagx="source" title="source">Trends Immunol</span>. <span class="year" tagx="year" title="year">2003</span>;<span class="volume" tagx="volume" title="volume">24</span>:<span class="fpage" tagx="fpage" title="fpage">474</span>â€�<span class="lpage" tagx="lpage" title="lpage">478</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12967670">12967670</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Casadevall</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Scharff</span><span class="given-names" tagx="given-names" title="given-names">MD</span></span>. <span class="mixed-article-title" title="mixed-article-title">Serum therapy revisited: animal models of infection and development of passive antibody therapy</span>. <span class="source" tagx="source" title="source">Antimicrob Agents Chemother</span>. <span class="year" tagx="year" title="year">1994</span>;<span class="volume" tagx="volume" title="volume">38</span>:<span class="fpage" tagx="fpage" title="fpage">1695</span>â€�<span class="lpage" tagx="lpage" title="lpage">1702</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/7985997">7985997</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rijnders</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span> Convalescent plasma as therapy for Covidâ€�19 severe SARSâ€�CoVâ€�2 disease (CONCOVID study) (ConCoVidâ€�19). <a href="http://clinicaltrials.gov">ClinicalTrialsgov</a> Identifier: NCT04342182</span></li> <li tag="ref"><a name="jca21806-bib-0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hendrickson</span><span class="given-names" tagx="given-names" title="given-names">JE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hillyer</span><span class="given-names" tagx="given-names" title="given-names">CD</span></span>. <span class="mixed-article-title" title="mixed-article-title">Noninfectious serious hazards of transfusion</span>. <span class="source" tagx="source" title="source">Anesth Analg</span>. <span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">108</span>:<span class="fpage" tagx="fpage" title="fpage">759</span>â€�<span class="lpage" tagx="lpage" title="lpage">769</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19224780">19224780</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Busch</span><span class="given-names" tagx="given-names" title="given-names">MP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bloch</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kleinman</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>. <span class="mixed-article-title" title="mixed-article-title">Prevention of transfusionâ€�transmittedinfections</span>. <span class="source" tagx="source" title="source">Blood</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">133</span>:<span class="fpage" tagx="fpage" title="fpage">1854</span>â€�<span class="lpage" tagx="lpage" title="lpage">1864</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30808637">30808637</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: AABB</span> . <span class="source" tagx="source" title="source">Standards for blood banks and transfusion services</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">AABB</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">Bethesda, MD</span>; <span class="year" tagx="year" title="year">2018</span>.</span></li> <li tag="ref"><a name="jca21806-bib-0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: FDA</span> . Electronic Code of Federal Regulations: 630.30 Donation suitability requirements. <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=630.3</a>. Updated March 17, 2020. Accessed March 19, <span class="year" tagx="year" title="year">2020</span>.</span></li> <li tag="ref"><a name="jca21806-bib-0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gao</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Detection of SARSâ€�CoVâ€�2 in different types of clinical specimens</span>. <span class="source" tagx="source" title="source">Jama</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">323</span>(<span class="issue" tagx="issue" title="issue">18</span>):<span class="fpage" tagx="fpage" title="fpage">1843</span><span class="pub-id"><a href="https://dx.doi.org/10.1001/jama.2020.3786">10.1001/jama.2020.3786</a></span>.</span></li> <li tag="ref"><a name="jca21806-bib-0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhao</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gong</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>. <span class="mixed-article-title" title="mixed-article-title">Severe acute respiratory SyndromeCoronavirus 2 RNA detected in blood donations</span>. <span class="source" tagx="source" title="source">Emerg Infect Dis</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">26</span>(<span class="issue" tagx="issue" title="issue">7</span>):<span class="fpage" tagx="fpage" title="fpage">1631</span>â€"<span class="lpage" tagx="lpage" title="lpage">1633</span>. <span class="pub-id"><a href="https://dx.doi.org/10.3201/eid2607.200839">10.3201/eid2607.200839</a></span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32243255">32243255</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Katzelnick</span><span class="given-names" tagx="given-names" title="given-names">LC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gresh</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Halloran</span><span class="given-names" tagx="given-names" title="given-names">ME</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Antibodyâ€�dependent enhancement of severe dengue disease in humans</span>. <span class="source" tagx="source" title="source">Science</span>. <span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">358</span>:<span class="fpage" tagx="fpage" title="fpage">929</span>â€�<span class="lpage" tagx="lpage" title="lpage">932</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29097492">29097492</a></span></span></li> <li tag="ref"><a name="jca21806-bib-0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tetro</span><span class="given-names" tagx="given-names" title="given-names">JA</span></span>. <span class="mixed-article-title" title="mixed-article-title">Is COVIDâ€�19 receiving ADE from other coronaviruses?</span><span class="source" tagx="source" title="source">Microbes Infect</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="fpage" tagx="fpage" title="fpage">72</span>â€�<span class="lpage" tagx="lpage" title="lpage">73</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32092539">32092539</a></span></span></li> </ul> </div> </div>  </body></html>